TPC · Form 4 · FELTENSTEIN SIDNEY J – TUTOR PERINI CORP

⌘K

Filings	Filing Date	Form Type	Company	Description	AI	Link

TPC · Form 4 · FELTENSTEIN SIDNEY J – TUTOR PERINI CORP | Signal8

Insider transactionsFund filings

Sort

Filings				Description
BRCBRADY CORP Nov 9, 2026 · 7:11 AM ET 8-K Brady Corporation announced the election of Scott J. Robinson and Kenneth J. Spangler to i… 5.02Officer/director change9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:11 AM ET	8-K	BRC BRADY CORP	5.02Officer/director change9.01ExhibitsExhibits:EX-99.1 Brady Corporation announced the election of Scott J. Robinson and Kenneth J. Spangler to its Board of Directors, effective November 9, 2026, while director Patrick W. Allender will…
SGCSUPERIOR GROUP OF COMPANIES, INC. Nov 9, 2026 · 7:10 AM ET 8-K Superior Group of Companies (SGC) reported Q3 2026 net sales of $146.0 million, up 5% from… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:10 AM ET	8-K	SGC SUPERIOR GROUP OF COMPANIES, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Superior Group of Companies (SGC) reported Q3 2026 net sales of $146.0 million, up 5% from $138.5 million a year ago, driven by growth in Branded Products and Contact Centers. Net…
AKAMAKAMAI TECHNOLOGIES INC Nov 9, 2026 · 7:10 AM ET 8-K Akamai announced on November 9, 2026 a proposed private offering of $1.1 billion of conver… 1.01Material agreement2.03Direct financial obligation8.01Other events+1Exhibits:EX-10.1EX-99.1	Nov 9, 20267:10 AM ET	8-K	AKAM AKAMAI TECHNOLOGIES INC	1.01Material agreement2.03Direct financial obligation8.01Other events+1Exhibits:EX-10.1EX-99.1 Akamai announced on November 9, 2026 a proposed private offering of $1.1 billion of convertible senior notes due 2028 and $1.1 billion due 2031, with initial purchasers holding opt…
IMVTImmunovant, Inc. Nov 9, 2026 · 7:09 AM ET 8-K Immunovant reported fiscal Q2 2026 results and clinical updates on November 9, 2026, ancho… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:09 AM ET	8-K	IMVT Immunovant, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Immunovant reported fiscal Q2 2026 results and clinical updates on November 9, 2026, anchored by positive Phase 2 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis. In…
OCULOCULAR THERAPEUTIX, INC Nov 9, 2026 · 7:08 AM ET 8-K Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2026 results with total revenue of $12.9 mil… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:08 AM ET	8-K	OCUL OCULAR THERAPEUTIX, INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2026 results with total revenue of $12.9 million, down from $14.5 million a year ago, and a net loss of $94.8 million ($0.42 per share…
HAINHAIN CELESTIAL GROUP INC Nov 9, 2026 · 7:07 AM ET 8-K Hain Celestial reported fiscal Q1 2027 net sales of $260 million, down 29% year over year,… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	HAIN HAIN CELESTIAL GROUP INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Hain Celestial reported fiscal Q1 2027 net sales of $260 million, down 29% year over year, with organic net sales down 7%. The net loss narrowed to $11 million ($0.12 per share) fr…
CEVACEVA INC Nov 9, 2026 · 7:07 AM ET 8-K Ceva (NASDAQ: CEVA) reported Q3 2026 revenues of $29.1 million, up 2% year-over-year, with… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	CEVA CEVA INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Ceva (NASDAQ: CEVA) reported Q3 2026 revenues of $29.1 million, up 2% year-over-year, with royalty revenues of $12.7 million up 3% YoY and 18% sequentially. The company posted rec…
ZURAZura Bio Ltd Nov 9, 2026 · 7:07 AM ET 8-KZura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in moderate-t… 8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	ZURA Zura Bio Ltd	8.01Other events9.01ExhibitsExhibits:EX-99.1 Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in moderate-to-severe hidradenitis suppurativa failed to meet its primary endpoint of change in abscess…
AMGAFFILIATED MANAGERS GROUP, INC. Nov 9, 2026 · 7:06 AM ET 8-K AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year o… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:06 AM ET	8-K	AMG AFFILIATED MANAGERS GROUP, INC.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1 AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year over year and Adjusted EBITDA of $353.7 million up 41%, while GAAP diluted EPS slipped to $…
FHTXFoghorn Therapeutics Inc. Nov 9, 2026 · 7:06 AM ET 8-K Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million… 2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:06 AM ET	8-K	FHTX Foghorn Therapeutics Inc.	2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2 Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million and net income of $58.2 million, a dramatic swing from a $15.8 million net loss a year ear…
KMDAKAMADA LTD Nov 9, 2026 · 7:05 AM ET 6-K Kamada reported record-high first nine months of 2026 results, with revenues of $152.2 mil… Exhibits:EX-99.1EX-99.2+2	Nov 9, 20267:05 AM ET	6-K	KMDA KAMADA LTD	Exhibits:EX-99.1EX-99.2+2 Kamada reported record-high first nine months of 2026 results, with revenues of $152.2 million (up 12% YoY), adjusted EBITDA of $40.9 million (up 20% YoY), and net income of $21.4…
WTTRSelect Water Solutions, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Select Water Solutions reported Q3 2026 revenue of $412 million, up 28% year-over-year, wi… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:05 AM ET	8-K	WTTR Select Water Solutions, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Select Water Solutions reported Q3 2026 revenue of $412 million, up 28% year-over-year, with net income of $23 million and Adjusted EBITDA of $93 million, up 57% year-over-year. T…
ELTKELTEK LTD Nov 9, 2026 · 7:05 AM ET 6-K Eltek Ltd. (NASDAQ: ELTK), an Israeli manufacturer of high-end printed circuit boards, ann… Exhibits:EX-99.1	Nov 9, 20267:05 AM ET	6-K	ELTK ELTEK LTD	Exhibits:EX-99.1 Eltek Ltd. (NASDAQ: ELTK), an Israeli manufacturer of high-end printed circuit boards, announced it will release its third quarter 2026 financial results before market open on Tues…
AURAAura Biosciences, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Aura Biosciences reported Q3 2026 results with a net loss of $32.1 million versus $26.1 mi… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:05 AM ET	8-K	AURA Aura Biosciences, Inc.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2 Aura Biosciences reported Q3 2026 results with a net loss of $32.1 million versus $26.1 million a year ago, and R&D expense of $24.7 million as its Phase 3 CoMpass trial of bel-sar…
VFFVillage Farms International, Inc. Nov 9, 2026 · 7:05 AM ET 8-K Village Farms reported Q3 2026 revenue of $66.9 million with record cannabis net sales of… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:05 AM ET	8-K	VFF Village Farms International, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Village Farms reported Q3 2026 revenue of $66.9 million with record cannabis net sales of $55 million, and its sixth consecutive quarter of positive net income at $10 million or $0…
EDITEditas Medicine, Inc. Nov 9, 2026 · 7:04 AM ET 8-K Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:04 AM ET	8-K	EDIT Editas Medicine, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Editas Medicine reported Q3 2026 results with a net loss of $23.4 million ($0.15 per share) on $10.4 million of collaboration revenue, up from $7.5 million a year ago on milestone…
TGTXTG THERAPEUTICS, INC. Nov 9, 2026 · 7:04 AM ET 8-K TG Therapeutics beat its stride in Q3 2026, posting $259.9 million in total revenue — up r… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:04 AM ET	8-K	TGTX TG THERAPEUTICS, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 TG Therapeutics beat its stride in Q3 2026, posting $259.9 million in total revenue — up roughly 61% year over year — including $232.6 million of BRIUMVI U.S. net product revenue,…
NWSANEWS CORP Nov 9, 2026 · 7:02 AM ET 8-KNews Corporation filed an 8-K attaching its daily ASX buy-back notifications for November… 8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:02 AM ET	8-K	NWSA NEWS CORP	8.01Other events9.01ExhibitsExhibits:EX-99.1EX-99.2 News Corporation filed an 8-K attaching its daily ASX buy-back notifications for November 6, 2026, covering its Nasdaq-listed Class A and Class B shares under the $1 billion 2025 R…
NRGNRG ENERGY, INC. Nov 9, 2026 · 7:02 AM ET 8-KNRG Energy announced a definitive agreement to sell six natural gas generation assets tota… 7.01Reg FD9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:02 AM ET	8-K	NRG NRG ENERGY, INC.	7.01Reg FD9.01ExhibitsExhibits:EX-99.1 NRG Energy announced a definitive agreement to sell six natural gas generation assets totaling 4.9 GW to an LS Power affiliate for $4 billion in cash, implying an 8.0x 2027 EV/Adj.…
PRAXPraxis Precision Medicines, Inc. Nov 9, 2026 · 7:02 AM ET 8-K Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million ($3.23 per share),… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:02 AM ET	8-K	PRAX Praxis Precision Medicines, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Praxis Precision Medicines reported a Q3 2026 net loss of $94.2 million ($3.23 per share), widening from $73.9 million a year ago, driven largely by a jump in G&A expenses to $42.7…

Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.

1-20 of 10,000+ filings